We recently published a list of 10 Firms Defy Market Slump, Record Double-Digit Gains Last Week. In this article, we are going to take a look at where Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stands against other firms that defied the market slump and recorded double-digit gains last week.
The stock market may have taken a beating for most of the week, but it was able to recover losses on Friday, as investors gobbled up shares while weighing the impact of the US-China trade war.
Among all major indices, the tech-heavy Nasdaq registered the highest gain, up 7.29 percent, followed by the S&P 500 with 5.7 percent, and the Dow Jones by 4.95 percent.
Ten companies, predominantly in the gold and biopharmaceutical sectors, were the week’s top performers as investors sought haven from their stocks amid market uncertainties.
In this article, we have identified last week’s 10 highest gainers and detailed the reasons behind their gains.
To come up with the list, we considered only the stocks with a $2 billion market capitalization and $5 million trading volume.
The week-on-week prices were based on the companies’ closing prices on Friday as against on April 4, or a week earlier.
A pharmacist in a hospital pharmacy stands next to a row of various drug containers.
Recursion Pharmaceuticals, a biotechnology company backed by Nvidia Corp., soared by 35.8 percent in just a week’s trading, finishing Friday at $27.72 versus the $4.24 close on April 4 as investor sentiment was buoyed by the Food and Drug Administration’s (FDA) decision to replace the use of animals in testing drugs with Artificial Intelligence.
RXRX is a clinical-stage biotechnology company that uses AI in its discovery and development processes. It is also one of the companies that received the backing of technology giant Nvidia Corp.
According to the FDA, the initiative was designed to replace animal testing with “more effective human-relevant methods” in the development of monoclonal antibody therapies and other drugs.
The move was not only expected to improve drug safety and expedite the evaluation process, but it could also result in lower research and development costs, thereby reducing drug prices for the end consumers.
According to the FDA, it will begin to encourage the inclusion of New Approach Methodologies (NAMs) data in investigational new drug applications.
Overall, RXRX ranks 1st on our list of firms that defied the market slump and recorded double-digit gains last week. While we acknowledge the potential of RXRX as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is as promising as RXRX but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.
